Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ONC206 |
Synonyms | |
Therapy Description |
ONC206 is an imipridone derivative that activates the stress response pathway, inhibits the p38MAPK/ERK and c-Myc pathways, glycolysis and oxidative phosphorylation, potentially leading to inhibition of cell proliferation, migration and tumor growth (PMID: 28489985, PMID: 32867127, PMID: 30037819) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ONC206 | ONC 206|ONC-206 | ONC206 is an imipridone derivative that activates the stress response pathway, inhibits the p38MAPK/ERK and c-Myc pathways, glycolysis and oxidative phosphorylation, potentially leading to inhibition of cell proliferation, migration and tumor growth (PMID: 28489985, PMID: 32867127, PMID: 30037819) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04541082 | Phase I | ONC206 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | Recruiting | USA | 0 |
NCT04732065 | Phase I | ONC206 | ONC206 for Treatment of Newly Diagnosed or Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant Brain Tumors (PNOC 023) | Recruiting | USA | CHE | 0 |